Two Sigma Investments LP Has $2.42 Million Stock Position in OPKO Health, Inc. (NASDAQ:OPK)

Two Sigma Investments LP grew its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 136.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,647,567 shares of the biotechnology company's stock after purchasing an additional 949,671 shares during the quarter. Two Sigma Investments LP owned approximately 0.24% of OPKO Health worth $2,422,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in OPK. ProShare Advisors LLC raised its position in shares of OPKO Health by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company's stock worth $135,000 after buying an additional 30,182 shares during the period. Nuveen Asset Management LLC grew its stake in shares of OPKO Health by 42.3% during the fourth quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company's stock valued at $2,106,000 after acquiring an additional 425,484 shares in the last quarter. Numerai GP LLC bought a new position in shares of OPKO Health during the fourth quarter worth about $205,000. Millennium Management LLC lifted its holdings in OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock worth $6,745,000 after buying an additional 2,112,382 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in OPKO Health by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company's stock worth $275,000 after buying an additional 8,064 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company's stock.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average cost of $1.70 per share, for a total transaction of $255,000.00. Following the completion of the purchase, the chief executive officer now directly owns 213,651,448 shares of the company's stock, valued at approximately $363,207,461.60. The trade was a 0.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have acquired 700,000 shares of company stock worth $1,123,000. Company insiders own 49.69% of the company's stock.

OPKO Health Stock Up 1.5%

OPK traded up $0.02 during trading on Monday, reaching $1.38. 4,242,498 shares of the stock traded hands, compared to its average volume of 3,876,604. OPKO Health, Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $2.04. The stock's 50-day simple moving average is $1.41 and its two-hundred day simple moving average is $1.54. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -7.26 and a beta of 1.42. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. OPKO Health's quarterly revenue was down 13.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. As a group, equities research analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on OPK. JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating on the stock. HC Wainwright reiterated a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday, April 7th. Barrington Research reaffirmed an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a research note on Thursday, May 1st. Finally, Wall Street Zen cut OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.